After more than a decade of phased implementation, policy refinements, and grace periods, the Drug Supply Chain Security Act (DSCSA) has entered full enforcement mode. The FDA is no longer simply educating stakeholders — it is actively issuing Form 483 observation letters to companies that fall short of compliance, with a sharp increase in activity leading into the 2025 interoperability deadline.
For manufacturers, wholesale distributors, and dispensers, this marks a turning point. The failure to maintain compliant, functional, and testable standard operating procedures (SOPs) is no longer an administrative oversight — it is a direct regulatory, operational, and reputational risk. And the impact is not only about compliance — these requirements are essential to protecting patients from counterfeit or illegitimate products.
The Enforcement Shift: From Policy to Penalty
DSCSA was enacted to create a unified, national framework for keeping counterfeit drugs out of the U.S. supply chain. The law was driven by a wave of high-profile incidents in the late 1990s and early 2000s, where counterfeiters exploited weaknesses in distribution, often through shell wholesalers and complex buyback schemes. These criminal operations allowed adulterated or fake drugs to reach patients, sometimes with harmful or fatal consequences.
In its early years, DSCSA deadlines were paired with education and infrastructure-building to give the industry time to adapt. That leniency has ended. Today, the FDA expects companies to demonstrate that their DSCSA requirements work in real time — verifying a suspicious batch, authenticating a returned product, or confirming a trading partner’s licensure before shipment.
Recent incidents underscore why enforcement is intensifying. High-value and high-demand medications such as HIV treatments and GLP-1 therapies have been targeted for counterfeiting and resale through fraudulent channels. In some cases, legitimate packaging was refilled with non-medicinal fillers or lower-cost tablets, then reintroduced into the supply chain. The ability to detect and respond to these threats now defines compliance.
Why SOPs Are in the Crosshairs
For many organizations, DSCSA readiness began as a technology build project — implementing serialization equipment, printing 2D barcodes, upgrading scanners, and enabling EPCIS data exchange. These tools are essential, but without governance and operational processes to support them, they cannot deliver the intended protections.
The FDA is finding common patterns in recent inspections:
- Outdated or incomplete SOPs that fail to reflect final DSCSA requirements
- Insufficient training
- Processes that have never been tested under real-world conditions
The root cause is often an overreliance on technology without equal investment in process and people. Effective SOPs ensure every employee — not just regulatory specialists — knows how to identify and escalate suspect product concerns. Just as adverse event reporting requires broad staff training, DSCSA compliance demands that anyone who might encounter a suspicious product can act immediately and in accordance with documented procedures.
483s Are the Starting Point – Not the End
A Form 483 is more than a formality — it is a clear signal that the FDA sees a breakdown in your compliance system and expects it to be addressed quickly. If corrective action is inadequate, these findings can escalate into warning letters, license delays, distribution holds, or more severe enforcement actions.
Beyond the regulatory consequences, Form 483s become public record, which can undermine market trust. For smaller or pre-commercial companies, a citation tied to DSCSA can raise red flags for investors, trading partners, and healthcare providers, all of whom expect a secure and reliable supply chain. As the agency does more inspections, the more they will learn and future inspections may become more robust over time.
Two Labs is also seeing an uptick at the state level that in order to obtain the necessary licensure to distribute product within or across state lines, that manufacturers must prove that they have DSCSA related SOPs in effect, otherwise distribution of pharmaceutical products are not allowed, exposing manufacturers to potential fines or lost sales. So it is not just the FDA that has the power to halt a manufacturer’s operations for insufficient SOPs.
Serialization: A Tool, Not the Solution
Serialization gives each product a unique identifier, much like a VIN on a vehicle, enabling verification and traceability throughout the supply chain. But just as a VIN alone cannot stop vehicle theft without supporting systems like registration and inspection, serialization cannot prevent counterfeit drugs without robust SOPs to act on the data it provides.
Manufacturers must be able to:
- Demonstrate that they have data integrity on their serialization information
- Verify products instantly when flagged as suspect
- Authenticate returned products before redistribution
- Confirm the status of trading partners before shipping or accepting goods
- Conduct thorough investigations and, if necessary notify trading partners and FDA
Closing the Gap & Becoming Inspection-Ready
This means ensuring SOPs are current, tested, and aligned with regulatory requirements; training all relevant teams — not just supply chain — to recognize and escalate potential risks; and validating that data reconciliation processes catch discrepancies before products move downstream.
The Two Labs DSCSA team helps manufacturers identify and close gaps before they result in findings. Services include comprehensive SOP reviews, data reviews, simulation-based testing of suspect product and returns handling, and providing education. Proactive audits have already helped companies uncover and correct vulnerabilities that could have led to costly enforcement actions.
Immediate priorities for manufacturers include:
- Conduct a DSCSA SOP audit focused on inspection readiness
- Retrain cross-functional teams to ensure real-world protocol adherence
- Run mock inspections to test high-risk processes
- Develop rapid-response playbooks for Form 3911 submissions and regulatory inquiries
Final Thought: The Time for Grace Periods Is Over
DSCSA enforcement is no longer a theoretical threat. It is now a coordinated, multi-level regulatory priority aimed at protecting patients from counterfeit or illegitimate products. Given the increase of GLP-1 counterfeit products making national headlines, the pressure is more palpable.
SOP failures are among the most visible — and preventable — compliance risks. Organizations that close these gaps now will not only meet regulatory expectations but also strengthen trust in the safety and integrity of their supply chains.
When DSCSA works as intended, patients never see the complex layers of verification that kept their medications safe — and that’s exactly how it should be. This is only one component of maintaining a resilient, compliant supply chain. In upcoming discussions, we will explore other critical operational areas that companies must address to remain inspection-ready and patient-focused in this new enforcement era.